Thursday, 21 March 2019

Aurobindo completes acquisition of Apotex’s five European Biz

13 February 2019 | News

The binding agreement to acquire five of Apotex' European businesses was announced on 14 July 2018.

image credit- cmo.com.au

image credit- cmo.com.au

Aurobindo Pharma Limited, a world-leading marketer and manufacturer of generic pharmaceuticals and active pharmaceutical ingredients, has announced that it has closed the acquisition of Apotex’s commercial operations and certain supporting infrastructure in five European countries.

The binding agreement to acquire five of Apotex' European businesses, including infrastructure, personnel, products, certain established trademarks, marketing authorizations and dossier license rights in Poland, the Czech Republic, the Netherlands (including the manufacturing facility in Leiden), Spain and Belgium was announced on 14 July 2018.

This announcement does not constitute a recommendation to shareholders or potential investors. Jefferies International Limited acted as sole financial advisor and Herbert Smith Freehills LLP acted as legal counsel to Aurobindo. Ernst & Young, India provided financial due diligence services.

Comments

× Your session has been expired. Please click here to Sign-in or Sign-up
   New User? Create Account






Survey Box

Can collaboration between startups and big life sciences companies offer a disruptive breakthrough?

× Please select an option to participate in the poll.
Processing...   View poll results   More polls

× You have successfully cast your vote.
{{ optionDetail.option }}{{ optionDetail.percentage }}%
{{ optionDetail.percentage }}% Complete
More polls